1.25 USD
-0.01
0.79%
Updated Apr 3, 3:02 PM EDT
1 day
-0.79%
5 days
-18.30%
1 month
-2.34%
3 months
-54.38%
6 months
-48.98%
Year to date
-53.70%
1 year
-42.40%
5 years
-92.83%
10 years
-92.83%
0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

125% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 12

67% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 5 (+2) [Q4]

33% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 39

11% more funds holding

Funds holding: 132 [Q3] → 146 (+14) [Q4]

1.19% less ownership

Funds ownership: 82.85% [Q3] → 81.66% (-1.19%) [Q4]

9% less capital invested

Capital invested by funds: $639M [Q3] → $579M (-$59.5M) [Q4]

78% less call options, than puts

Call options by funds: $42K | Put options by funds: $195K

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$3
140%
upside
Avg. target
$4.60
268%
upside
High target
$6
380%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
Raymond James
Laura Prendergast
17% 1-year accuracy
1 / 6 met price target
300%upside
$5
Outperform
Initiated
26 Mar 2025
Goldman Sachs
Chris Shibutani
25% 1-year accuracy
3 / 12 met price target
140%upside
$3
Buy
Maintained
21 Mar 2025
HC Wainwright & Co.
Andres Maldonado
18% 1-year accuracy
9 / 51 met price target
380%upside
$6
Buy
Reiterated
21 Mar 2025
Morgan Stanley
Jeffrey Hung
0% 1-year accuracy
0 / 5 met price target
220%upside
$4
Overweight
Assumed
7 Mar 2025
B of A Securities
Alec Stranahan
0% 1-year accuracy
0 / 3 met price target
300%upside
$5
Buy
Upgraded
7 Jan 2025

Financial journalist opinion

Neutral
GlobeNewsWire
1 week ago
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will present three poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25 - 30, 2025, in Chicago, Illinois. The abstracts will be available on the AACR 2025 meeting website.
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
Neutral
GlobeNewsWire
1 week ago
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results
Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results
Neutral
GlobeNewsWire
2 months ago
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace in New York, New York. Management will participate in a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will also participate in one-on-one investor meetings.
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference
Positive
Seeking Alpha
2 months ago
Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma
Naporafenib is Erasca's main candidate, and it has Fast Track status for NRASm melanoma. I see the company has a robust balance sheet, with roughly $463.3 million in cash and equivalents as of Q3, 2024. They estimate a runway into 2H2027. SEACRAFT-1 already showed that Naporafenib has potentially better efficacy compared to the SoC and competitors.
Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma
Positive
Zacks Investment Research
2 months ago
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
Positive
Zacks Investment Research
2 months ago
Down -27.17% in 4 Weeks, Here's Why Erasca (ERAS) Looks Ripe for a Turnaround
Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -27.17% in 4 Weeks, Here's Why Erasca (ERAS) Looks Ripe for a Turnaround
Positive
Zacks Investment Research
2 months ago
Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
Positive
Zacks Investment Research
2 months ago
Down -22.89% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -22.89% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
Positive
Zacks Investment Research
4 months ago
Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Erasca (ERAS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Neutral
GlobeNewsWire
4 months ago
Erasca Reports Third Quarter 2024 Business Updates and Financial Results
Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025
Erasca Reports Third Quarter 2024 Business Updates and Financial Results
Charts implemented using Lightweight Charts™